文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

接受体外膜氧合的COVID-19患者出血与血栓事件:基于COVID-19重症监护联盟的国际研究

Hemorrhage and thrombosis in COVID-19-patients supported with extracorporeal membrane oxygenation: an international study based on the COVID-19 critical care consortium.
PubMed 文献 · J Intensive Care · 2024-05-06
一句话结论国际注册数据显示,接受ECMO的COVID-19重症ARDS患者中38%发生凝血并发症,单纯出血并发症与ICU死亡风险升高独立相关(校正HR=1.60)。

该研究基于COVID-19重症监护联盟数据库,回顾性分析2020年1月至2022年6月全球多中心接受ECMO的成人重症COVID-19患者,评估出血与凝血障碍与ICU死亡风险的关系。在1248例接受ECMO支持的患者中,469例(38%)报告凝血并发症,其中252例(54%)为出血并发症、165例(35%)为血栓并发症、52例(11%)两者兼有。单纯出血并发症患者ICU死亡风险高于无并发症者(校正HR=1.60,95%CI 1.28-1.99,p<0.001)。1248例中617例(49.4%)死亡,主要死因为多器官衰竭(257/617,42%)、呼吸衰竭(130/617,21%)和脓毒性休克(55/617,8.9%)。作者认为凝血障碍在ECMO支持的COVID-19 ARDS患者中常见,出血事件对该队列死亡有实质贡献,但风险可能低于既往单国研究或早期病例报告。

要点

  • 1248例接受ECMO的COVID-19重症ARDS患者中,469例(38%)发生凝血并发症。
  • 凝血并发症中出血252例(54%)、血栓165例(35%)、两者兼有52例(11%)。
  • 单纯出血并发症者ICU死亡风险高于无并发症者(校正HR=1.60,95%CI 1.28-1.99,p<0.001)。
  • 1248例中617例(49.4%)死亡,主要死因为多器官衰竭(42%)、呼吸衰竭(21%)和脓毒性休克(8.9%)。
  • 作者认为出血事件对该队列死亡有实质贡献,但风险可能低于既往单国研究或早期病例报告。

适用人群与场景

  • 2020年1月至2022年6月全球多中心数据库中接受ECMO支持的成人重症COVID-19患者。

研究设计与关键结果

  • 研究类型:基于COVID-19重症监护联盟数据库的回顾性分析,纳入2020年1月至2022年6月全球多中心接受ECMO的成人重症COVID-19患者。
  • 共1248例接受ECMO支持,凝血并发症469例(38%),其中出血252例(54%)、血栓165例(35%)、两者兼有52例(11%)。
  • 单纯出血并发症者ICU死亡风险高于无并发症者(校正HR=1.60,95%CI 1.28-1.99,p<0.001)。
  • 1248例中617例(49.4%)死亡,主要死因依次为多器官衰竭(257/617,42%)、呼吸衰竭(130/617,21%)、脓毒性休克(55/617,8.9%)。

证据类型、等级与局限

  • 证据类型:基于国际多中心注册数据库的回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为凝血障碍在ECMO支持的COVID-19 ARDS患者中常见,出血事件对该队列死亡有实质贡献,但风险可能低于既往单国研究或早期病例报告。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Extracorporeal membrane oxygenation (ECMO) is a rescue therapy in patients with severe acute respiratory distress syndrome (ARDS) secondary to COVID-19. While bleeding and thrombosis complicate ECMO, these events may also occur secondary to COVID-19. Data regarding bleeding and thrombotic events in COVID-19 patients on ECMO are sparse.

METHODS: Using the COVID-19 Critical Care Consortium database, we conducted a retrospective analysis on adult patients with severe COVID-19 requiring ECMO, including centers globally from 01/2020 to 06/2022, to determine the risk of ICU mortality associated with the occurrence of bleeding and clotting disorders.

RESULTS: Among 1,248 COVID-19 patients receiving ECMO support in the registry, coagulation complications were reported in 469 cases (38%), among whom 252 (54%) experienced hemorrhagic complications, 165 (35%) thrombotic complications, and 52 (11%) both. The hazard ratio (HR) for Intensive Care Unit mortality was higher in those with hemorrhagic-only complications than those with neither complication (adjusted HR = 1.60, 95% CI 1.28-1.99, p < 0.001). Death was reported in 617 of the 1248 (49.4%) with multiorgan failure (n = 257 of 617 [42%]), followed by respiratory failure (n = 130 of 617 [21%]) and septic shock [n = 55 of 617 (8.9%)] the leading causes.

CONCLUSIONS: Coagulation disorders are frequent in COVID-19 ARDS patients receiving ECMO. Bleeding events contribute substantially to mortality in this cohort. However, this risk may be lower than previously reported in single-nation studies or early case reports. Trial registration ACTRN12620000421932 ( https://covid19.cochrane.org/studies/crs-13513201 ).

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Feth M, Weaver N, Fanning RB, et al. Hemorrhage and thrombosis in COVID-19-patients supported with extracorporeal membrane oxygenation: an international study based on the COVID-19 critical care consortium. J Intensive Care. 2024. PMID: 38711092. doi:10.1186/s40560-024-00726-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。